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1. INTRODUCTION {#cam42124-sec-0005}
===============

Oral squamous cell carcinoma (OSCC) continues to be an important burden on health care, with an increasing incidence and only moderately improving survival.[1](#cam42124-bib-0001){ref-type="ref"}, [2](#cam42124-bib-0002){ref-type="ref"}, [3](#cam42124-bib-0003){ref-type="ref"}, [4](#cam42124-bib-0004){ref-type="ref"}‐45% of OSCC patients will develop local‐ or regional recurrence (LRR), a second primary tumor (SPT) or distant metastasis (DM) (further called second events) after primary curative‐intent treatment.[4](#cam42124-bib-0004){ref-type="ref"}, [5](#cam42124-bib-0005){ref-type="ref"} Current guideline‐recommendations advocate follow‐up after curative treatment for all patients of at least 5 years.[6](#cam42124-bib-0006){ref-type="ref"} The main reason for follow‐up is the early detection of second events; other goals are functional rehabilitation and psychosocial support.

Follow‐up guidelines are not evidence‐ but consensus‐based. Empirical studies on follow‐up after treatment for OSCC are scarce and usually combine the data of all HNC\'s, which have a different etiology, treatment, prognosis, and timing of second events.[7](#cam42124-bib-0007){ref-type="ref"}, [8](#cam42124-bib-0008){ref-type="ref"}, [9](#cam42124-bib-0009){ref-type="ref"} The available studies on OSCC are small and do not address the question whether specific patient groups are in need of more or less intensive follow‐up.[10](#cam42124-bib-0010){ref-type="ref"}, [11](#cam42124-bib-0011){ref-type="ref"}, [12](#cam42124-bib-0012){ref-type="ref"}, [13](#cam42124-bib-0013){ref-type="ref"}

The current "one‐size‐fits‐all" follow‐up programs can be criticized on several points.[14](#cam42124-bib-0014){ref-type="ref"}, [15](#cam42124-bib-0015){ref-type="ref"} Firstly, it is questionable if such a program is beneficial to all patients as some may be at higher risk of a second event than others.[16](#cam42124-bib-0016){ref-type="ref"}, [17](#cam42124-bib-0017){ref-type="ref"} The time frame of 5 years is debatable as most tumors seem to recur in the first few years.[7](#cam42124-bib-0007){ref-type="ref"}, [12](#cam42124-bib-0012){ref-type="ref"} Furthermore, it has never been investigated whether patients should receive a different follow‐up schedule after curative‐intent treatment of a second event.

It is of utmost importance to optimize and personalize OSCC follow‐up to avoid unnecessary testing and anxiety in patients, optimize the use of health care resources and minimize the time clinicians spend on ineffective follow‐up consultations. Therefore, this study investigates the time patterns, risks, and treatment intent of second and subsequent events after curative‐intent treatment of OSCC.

2. MATERIALS AND METHODS {#cam42124-sec-0006}
========================

2.1. Patients {#cam42124-sec-0007}
-------------

Between 2000 and 2012, 756 patients were diagnosed with primary OSCC (ICD O codes C.00‐06 excluding C.01, C.05.1 en C.05.2) and treated at the Head and Neck Cancer Unit of the Radboud University Medical Centre. Of these patients, 57 were excluded from analysis for the following reasons: not a first primary OSCC (*n* = 23), a previous or synchronous tumor in other subsites of the head and neck area (*n* = 32) and other reasons (*n* = 2). Of the remaining 699 patients, 594 (85%) were treated with curative intent and eligible for analysis.

Patients were staged according to the seventh UICC TNM classification. Treatment intent and therapy choices were based on the Dutch national guideline. Decisions concerning therapy and treatment intent were taken after discussion in a multidisciplinary team meeting.[15](#cam42124-bib-0015){ref-type="ref"}

Patients received follow‐up examinations every 2 and 3 months during the first and second year posttreatment, respectively, every 4 months in the third year and every 6 months during the fourth and fifth year. Survival was updated in November 2014 using the municipal registration of deaths.

The difference between a LRR and a SPT was based on p53 mutation analysis. If unavailable, the modified Warren and Gates criteria as described by Re et al were used.[18](#cam42124-bib-0018){ref-type="ref"}, [19](#cam42124-bib-0019){ref-type="ref"}

2.2. Statistical analysis {#cam42124-sec-0008}
-------------------------

Overall survival (OS) from the date of last primary treatment was calculated with the Kaplan‐Meier method. Median follow‐up time was determined by the inverse Kaplan‐Meier method (censored data as events).

Risk of recurrence was calculated using competing risk methods with death from intercurrent disease as competing event.[20](#cam42124-bib-0020){ref-type="ref"} Conditional risk of recurrence per follow‐up year was defined as the probability of experiencing a recurrence in that year (*y*), given that the patient had been recurrence‐free up to the previous follow‐up year (*x*). Annual conditional risk of event is calculated by dividing the cumulative risk of event‐free survival at "*x* + y" years after primary treatment by the cumulative risk at "*x*" years after treatment.[21](#cam42124-bib-0021){ref-type="ref"} Risk estimates are given with 95% confidence intervals (CI).

Independent prognostic factors were selected through forward stepwise regression with *P* \< 0.10 as a cutoff. The Fine and Gray modified Cox proportional hazards model was used to determine prognostic factors for risk of recurrence. The hazard rate ratio\'s (sHR) for the final model including the selected prognostic factors were presented. The observed 5‐year risks of recurrence for all combination of the selected prognostic variables were determined, categorized and presented in a flow chart. Logistic regression was performed to identify prognostic factors for the probability of curative‐intent treatment. For the final model including the selected factors, the odds ratios (OR) were presented, and the observed proportion of second events treated with curative intent categorized. The potential prognostic factors studied are presented in the (Table [S1](#cam42124-sup-0002){ref-type="supplementary-material"}).

3. RESULTS {#cam42124-sec-0009}
==========

3.1. First event {#cam42124-sec-0010}
----------------

The patient, tumor, and treatment characteristic of 594 patients treated with curative intent for primary OSCC (first event) are displayed in Table [1](#cam42124-tbl-0001){ref-type="table"}.

###### 

Patient, tumor and treatment characteristics, and survival and recurrence rates of patients treated for primary (*N* = 594) and recurrent (*N* = 106) OSCC with curative intent

                                                                         First event (*N* = 594)                   Second event (*N* = 106)                          
  ---------------------------------------------------------------------- ----------------------------------------- -------------------------- ---------------- ----- -----
  Overall                                                                                                          594                                         106   
  *Patient characteristics*                                                                                                                                          
   Gender                                                                Male                                      359                        60%              62    58%
  Female                                                                 235                                       40%                        44               42%   
   Age at diagnosis                                                      \<40 years                                24                         4%               6     6%
  40‐60 years                                                            237                                       40%                        32               30%   
  ≥60 years                                                              333                                       56%                        68               64%   
   ASA score at primary diagnosis                                        I                                         145                        24%              29    27%
  II                                                                     323                                       54%                        59               56%   
  III                                                                    96                                        16%                        13               12%   
  IV                                                                     2                                         1%                         --               --    
  Unknown                                                                28                                        5%                         5                5%    
   Malignancies in the past (primary diagnosis)                          Yes                                       35                         6%               2     2%
  No                                                                     559                                       94%                        104              98%   
   Oral premalignancies in the past (primary diagnosis)                  Yes                                       27                         4%               12    11%
  No                                                                     564                                       95%                        94               89%   
  Unknown                                                                3                                         1%                         --               --    
   Karnofsky Performance Score at primary diagnosis                      \<60                                      3                          1%               --    --
  60                                                                     13                                        2%                         --               --    
  70                                                                     18                                        3%                         2                2%    
  80                                                                     32                                        6%                         7                7%    
  90                                                                     79                                        13%                        12               11%   
  100                                                                    55                                        9%                         16               15%   
  Unknown                                                                394                                       66%                        69               65%   
   Smoking and alcohol at primary diagnosis                              Never smoker, none‐moderate alcohol use   96                         16%              25    24%
  Never smoker, problematic alcohol use                                  3                                         1%                         0                --    
  (ex) smoker, none‐moderate alcohol use                                 217                                       36%                        38               36%   
  (ex) smoker, problematic alcohol use                                   206                                       35%                        31               29%   
  Unknown                                                                72                                        12%                        12               11%   
  *Tumor characteristics*                                                                                                                                            
   Tumor stage                                                           1                                         222                        37%              36    34%
  2                                                                      214                                       36%                        10               9%    
  3                                                                      45                                        8%                         5                5%    
  4 (a+b)                                                                113                                       19%                        5                5%    
  Unknown                                                                --                                        --                         50               47%   
   Nodal stage                                                           0                                         368                        62%              55    52%
  1                                                                      68                                        12%                        17               16%   
  2                                                                      127                                       21%                        10               9%    
  Unknown                                                                31                                        5%                         24               23%   
   Stage                                                                 1                                         177                        30%              33    31%
  2                                                                      129                                       22%                        8                8%    
  3                                                                      68                                        11%                        9                8%    
  4                                                                      189                                       32%                        6                6%    
  Unknown                                                                31                                        5%                         50               47%   
   Location                                                              Tongue                                    216                        36%              20    19%
  Buccal mucosa                                                          48                                        8%                         9                8%    
  Floor of the mouth                                                     208                                       35%                        16               15%   
  Retromolar trigone                                                     52                                        9%                         4                4%    
  Alveolar process                                                       66                                        11%                        14               13%   
  Other                                                                  4                                         1%                         43               41%   
  *Treatment characteristics*                                                                                                                                        
   Therapy                                                               Surgery only                              260                        44%              53    50%
  Radiotherapy only                                                      11                                        2%                         8                8%    
  Surgery and radiotherapy                                               276                                       46%                        28               26%   
  Surgery and chemoradiation                                             27                                        5%                         8                8%    
  Chemoradiation                                                         20                                        3%                         6                5%    
  Chemotherapy only                                                      --                                                                   2                2%    
  Surgery and chemotherapy                                               --                                                                   1                1%    
   Surgery                                                               Yes                                       563                        95%              89    84%
  No                                                                     31                                        5%                         17               16%   
   Optimal treatment as advised by the multi disciplinary team meeting   Yes                                       509                        86%              82    77%
  No                                                                     78                                        13%                        22               21%   
  Unknown                                                                7                                         1%                         2                2%    
   *Follow‐up characteristics*                                                                                                                                       
   Follow‐up time                                                        Median (range) years                      7.8 (0.1‐14.5)             6.0 (0.1‐13.0)         
   5‐year overall survival                                               \% (95% CI)                               65% (61%;69%)              64% (52%;74%)          
   5‐year CIF recurrence                                                 \% (95% CI) recurrence                    30% (26%;33%)              36% (26%;46%)          
   5‐year CIF competing event                                            \% (95% CI) intercurrent death            17% (14%;20%)              21% (13%;31%)          

John Wiley & Sons, Ltd

### 3.1.1. Risk of a second event {#cam42124-sec-0011}

The 1‐, 5‐, and 10‐year cumulative risks of a second event (ie recurrence, new primary tumor or DM) were 17% (CI:14%;20%), 30% (CI:26%;33%) and 37% (CI:32%;41%). The majority of LRR occurred within the first year after treatment, and all the DMs within 3 years. The incidence rate of SPTs was stable over the entire follow‐up period (Figure [1](#cam42124-fig-0001){ref-type="fig"}A).

![Cumulative risk of second event (A,B), annual conditional risk of second event by event type (C,D) and treatment intent (E,F). (A) Cumulative risk of a second event, by event type. (B) Cumulative risk of a third event, by event type. (C) Annual conditional risk of a second event, by event type. (D) Annual conditional risk of a third event, by event type. (E) Annual conditional risk of a second event, by treatment intent. (F) Annual conditional risk of a third event, by treatment intent](CAM4-8-5810-g001){#cam42124-fig-0001}

Annual *conditional* risk of a second event was highest in the first year of follow‐up. that is, 17% and decreasing in the following years (Figure [1](#cam42124-fig-0001){ref-type="fig"}C). Annual conditional risks of a second event were higher for the nonsurgically treated group compared with the surgically treated group (Figure [S1](#cam42124-sup-0001){ref-type="supplementary-material"}).

Surgical primary treatment was a statistically significant prognostic factor for risk of a second event (*P*‐value Gray test: \<0.01). The 5‐year cumulative risk was 28% (CI:25%;32%) after surgical treatment and 50% (CI:31%;67%) after nonsurgical treatment. In patients treated surgically, vasoinvasive growth, cervical lymph node dissection, buccal mucosa, and extranodal growth were important independent prognostic factors for risk of second event (Table [2](#cam42124-tbl-0002){ref-type="table"}). Based on these factors, a flowchart was built with corresponding 5‐year cumulative risks of a second event (Figure [2](#cam42124-fig-0002){ref-type="fig"}). Nine risk groups, with an observed 5‐year risk of second event varying between \<10% for patients who received surgical treatment and had a previous malignancy and 50%, for patients without surgical treatment were identified. The group size of the nonsurgically treated group did not permit further risk stratification, but were considered as separate risk group.

###### 

Independent prognostic factors for the risk of recurrence after curative‐intent surgical treatment for primary OSCC: results from the forward selection procedure

  Prognostic factor                        sHR (95% CI)
  ---------------------------------------- ----------------
  Vasoinvasive growth (yes vs no)          1.6 (1.1; 2.2)
  Cervical node dissection (yes vs no)     0.6 (0.4; 0.8)
  Buccal mucosa (vs all other locations)   2.1 (1.3; 3.3)
  Extranodal growth (yes vs no)            1.6 (1.0; 2.5)

John Wiley & Sons, Ltd

![Flow chart for the observed 5‐year cumulative risk of a second event after curative‐intent treatment for OSCC](CAM4-8-5810-g002){#cam42124-fig-0002}

### 3.1.2. Treatment intent {#cam42124-sec-0013}

The proportion of the 193 second events that could be treated with curative intent increased with follow‐up time from 32% (CI:20%;45%) for early recurrences (0‐6 months after treatment) to 71% (CI:57%;69%) for patients who had a second event 24‐60 months after treatment. The annual conditional risk of a second event that could not be treated curatively was highest in the first year after treatment (Figure [1](#cam42124-fig-0001){ref-type="fig"}E). The proportion of patients with a LRR that could be treated curatively decreased, while the proportion of patients with a SPT that could be treated curatively was stable over time.

Patients having their recurrence detected after primary surgical treatment had a higher chance of curative treatment of the second event when compared with recurrences detected after non‐surgical treatment: 58% (CI:50%;65%) vs 25% (CI:10%;50%). In patients treated surgically, postoperative radiotherapy for the first event, tumor size, nodal status, ASA‐score, and invasion depth were important independent prognostic factors for curative‐intent treatment of a second event (Table [3](#cam42124-tbl-0003){ref-type="table"}). Based on the number of risk factors, the chance of curative intent treatment varied between 0% (four risk factors) and 96% (no risk factors) (Table [4](#cam42124-tbl-0004){ref-type="table"}).

###### 

Independent prognostic factors for the treatment intent of second events after curative‐intent surgical treatment for primary OSCC: results from the forward selection procedure

  Prognostic factor                 OR (95% CI)
  --------------------------------- ----------------
  Radiotherapy (yes vs no)          0.1 (0.0; 0.4)
  Nodal stage 2 (vs stage 0 or 1)   0.2 (0.1; 0.5)
  Tumor stage 4 (vs stage 1‐3)      0.1 (0.0; 0.5)
  ASA III or IV (vs ASA I or II)    0.1 (0.0; 0.4)
  Invasion dept ≥4 mm (vs \<4 mm)   0.3 (0.1;1.3)

John Wiley & Sons, Ltd

###### 

The observed proportion of patients with their second event treated with curative intent related to the number of risk factors, relating to the first primary OSCC (radiotherapy, pN~2~, pT~4~, ASA3/4, invasion depth \>4 mm)

  Number of risk factors                            Number of patients   Observed % curative intent   (95% CI)
  ------------------------------------------------- -------------------- ---------------------------- -----------------------------------------------
  0                                                 27                   96%                          81%‐100%
  1                                                 30                   97%                          83%‐100%
  2                                                 39                   62%                          45%‐77%
  3                                                 38                   26%                          13%‐43%
  4                                                 12                   0%                           0%‐26%[a](#cam42124-note-0001){ref-type="fn"}
  Missing information on one or more risk factors   31                   42%                          25%‐61%

One‐sided, 97.5% confidence interval.

John Wiley & Sons, Ltd

3.2. Second event {#cam42124-sec-0014}
-----------------

The characteristics of the 106 patients curatively treated for a second event are summarized in Table [1](#cam42124-tbl-0001){ref-type="table"}. The 5‐year OS rate after completion of the treatment of the second event was 49% (CI:38%;59%).

### 3.2.1. Risk of a third event {#cam42124-sec-0017}

The 1‐, 5‐, and 10‐year cumulative risks of a third event were 23% (CI:16;32%), 37% (CI:27%;47%), and 45% (CI:32%;57%). Almost all local and/or regional recurrences occurred within 2 years after treatment (Figure [1](#cam42124-fig-0001){ref-type="fig"}B). The risk of a new primary tumor as third event was constant over time.

The annual *conditional* risk of a third event was 24% in the first year after treatment, 7% in the second year and decreased to 4% in the fifth year after treatment (Figure [1](#cam42124-fig-0001){ref-type="fig"}D).

The risk for a third event did not significantly differ between patients treated with (*n* = 88) and without (*n* = 17) surgery for their second event (*P*‐value Gray test: 0.42). The number of third events was too small (*n* = 38) for a reliable search for independent prognostic factors. However, univariable analyses for prognostic factors for the risk of a third event showed similar trends when compared with univariable analyses for the risk of a second event (Table [S1](#cam42124-sup-0002){ref-type="supplementary-material"}).

### 3.2.2. Treatment intent {#cam42124-sec-0018}

Of the 38 third events, 16 (42%) could be treated with curative intent (Figure [1](#cam42124-fig-0001){ref-type="fig"}F). SPTs were more often treated with curative intent (58%) than LRRs (39%). None of the three DMs were treated with curative intent. Patient numbers were too small to draw conclusions about the trends in time or to reliably compare prognostic factors for treatment intent for second vs third events. Patient‐ and tumor‐related factors for second and third events and their relationship with treatment intent are presented in the appendix (Table [S2](#cam42124-sup-0002){ref-type="supplementary-material"}).

4. DISCUSSION {#cam42124-sec-0019}
=============

This study is the first comprehensive analysis of patterns of occurrence of new disease that focuses specifically on OSCC. First and second events which include both recurrences and SPTs in a large cohort with a long follow‐up time are described. The cumulative risk of recurrence for both surgically and nonsurgically treated patients was highest in the first year after treatment. Almost all LRRs occurred in the first 2 years after treatment. The incidence of SPTs was stable over the years. The time patterns of presentation of third events did not differ from that of second events. Our results are clinically highly relevant, because these patterns are not adequately reflected in the current guidelines for routine follow‐up after OSCC treatment which advocate 5 year or lifelong follow‐up after the treatment for OSCC.[15](#cam42124-bib-0015){ref-type="ref"}, [22](#cam42124-bib-0022){ref-type="ref"} Determining the optimal follow‐up schedule is very important from a patient\'s perspective, because unnecessary follow‐up will create unnecessary anxiety and false expectations.

Our results are consistent with the results from other authors who reported that 86%‐94% of new disease after curatively treated OSCC occurred within 2 years.[11](#cam42124-bib-0011){ref-type="ref"}, [12](#cam42124-bib-0012){ref-type="ref"}, [23](#cam42124-bib-0023){ref-type="ref"}, [24](#cam42124-bib-0024){ref-type="ref"} Consistent with Vaamonde et al we confirm that the risk for a SPT is stable over time.[25](#cam42124-bib-0025){ref-type="ref"}

Arguments for lifelong follow‐up are based on the assumption that early, asymptomatic, detection of new primary tumors leads to improved survival. The literature, which comprises all HNCs rather than the oral cavity alone, remains equivocal on this subject.[26](#cam42124-bib-0026){ref-type="ref"} Site‐specific studies on laryngeal carcinomas and early‐stage OSCC did not show survival benefits.[27](#cam42124-bib-0027){ref-type="ref"} The proportion of patients treated with curative intent in our study did not differ between SPTs detected within 5 years (ie during the follow‐up period) and those detected after 5 years, suggesting that it is safe to shorten the follow‐up period. When shortening the follow‐up program, it is important to educate patients about the symptoms of new disease and provide them easy access to the clinic in case of symptoms.[28](#cam42124-bib-0028){ref-type="ref"}

If follow‐up is proven to be beneficial to patients, customization of follow‐up schedules based on risk of recurrence can be beneficial. Using 6 independent prognostic factors, namely surgical treatment, previous malignancy, presence of vasoinvasive growth, neck dissection, localization of the tumor and the presence of extranodal growth, we were able to identify patient groups with 5‐year risks of a second event varying between \<10% and 50%. The prognostic value of these factors has been confirmed by several other authors.[29](#cam42124-bib-0029){ref-type="ref"}, [30](#cam42124-bib-0030){ref-type="ref"} In our patient group the risk of recurrence between the different locations differed significantly (*P* \< 0.01). The literature concerning the effect of location on the risk of recurrence is not unequivocal, with some authors reporting a significant effect on the risk of recurrence[31](#cam42124-bib-0031){ref-type="ref"}, [32](#cam42124-bib-0032){ref-type="ref"} and others not.[33](#cam42124-bib-0033){ref-type="ref"}, [34](#cam42124-bib-0034){ref-type="ref"} This reflects the complex multifactorial nature of oral cancer, which goes beyond purely anatomical factors.

Of interest is also that patients with a previous malignancy have a statistically significant lower risk of second events. This is likely to be caused by the fact that they have a higher risk of intercurrent death from other causes (data not shown). Another important prognostic factor for a second event was if the patient underwent an elective neck dissection for the treatment of their first primary tumor. This can partially be explained by the fact that patients with a clinically negative neck, a small tumor and an invasion depth \<4 mm did not undergo an elective neck dissection. Montero et al built a nomogram predicting the probability of LRR‐free survival comprising nodal status, the subsites, bone invasion and primary tumor size.[35](#cam42124-bib-0035){ref-type="ref"} These parameters largely overlap ours. If routine follow‐up is considered effective, the nomograms for the risk of a second event might aid the development of a personalized follow‐up program, but should undergo further detailed evaluation and validation.

Another way to personalize follow‐up is by considering the chance of curative intent treatment of a second event. This strategy has been advocated by Kanatas et al, who suggested that patients with early disease who were treated with a single modality, might benefit from earlier discharge.[36](#cam42124-bib-0036){ref-type="ref"} Patients who develop DM will have no chance to be cured. The likelihood of curative intent treatment of the second event could be predicted using 5 factors, that is previous radiotherapy, nodal status of the first primary tumor, tumor size, invasion depth, and ASA‐score resulting in observed probabilities ranging between 0% and 96%. The factors associated with a treatment with curative intent are all related to the possibilities a patient has left to receive therapy. Many patients will have undergone treatment for the neck consisting of neck dissection and/or (chemo)radiotherapy.[4](#cam42124-bib-0004){ref-type="ref"} Several authors confirmed that patients with previous neck dissections had a markedly smaller chance of successful salvage surgery.[24](#cam42124-bib-0024){ref-type="ref"}, [37](#cam42124-bib-0037){ref-type="ref"}, [38](#cam42124-bib-0038){ref-type="ref"} Likewise, in most patients who had previous radiotherapy another course of radiotherapy will not be possible.[39](#cam42124-bib-0039){ref-type="ref"}

Other authors mentioned performance status, ASA‐score and previous quality of life as important factors for a successful salvage.[9](#cam42124-bib-0009){ref-type="ref"} Our results confirm that time to recurrence yields important prognostic information for the success of salvage.[24](#cam42124-bib-0024){ref-type="ref"}, [40](#cam42124-bib-0040){ref-type="ref"}, [41](#cam42124-bib-0041){ref-type="ref"} This is the first attempt to determine subgroups of patients for whom curative treatment of second events may be available. Patients who are unlikely to be treated curatively for their next event might benefit from a follow‐up program that focuses more on quality of life than on the early detection of new disease.

A limitation of this study is that changes in patient‐related factors such as smoking, alcohol use and ASA‐score could not be taken into account as these data were only available at the time of the first diagnosis.[42](#cam42124-bib-0042){ref-type="ref"} As the Karnofsky score was only available in 44% of the patients, we could not include this parameter in our prediction models.

Strengths of this study are the large, site‐specific patient cohort that was followed by a strict protocol with very high compliance rates and the description both first and second events. By the use of competing‐risk analysis, a more accurate estimation of absolute risks is given than the Kaplan‐Meier method which usually overestimates the cumulative risk of events when competing risks, like mortality, occur.

Our study shows that a 2‐year follow‐up period is sufficient for the detection of LRRs. Longer follow‐up may be indicated on an individual basis for treatment‐related morbidities and dental rehabilitation.[43](#cam42124-bib-0043){ref-type="ref"}, [44](#cam42124-bib-0044){ref-type="ref"} We therefore advocate a personalized follow‐up schedule with a "core follow‐up" for 2 years after which frequency, type of clinician and duration are tailored to the patient\'s needs. In order to timely diagnose new disease after discharge, patients should be educated to recognize symptoms of new disease.[36](#cam42124-bib-0036){ref-type="ref"}

Our findings support a follow‐up time of 2 years after curative‐intent treatment for OSCC. Longer follow‐up may be needed for some individual patients due to treatment‐related morbidities and psychological needs. Based on the patterns of occurrence of third events, a separate follow‐up protocol after curative treatment of a second event is not needed. The 2 prediction models developed in this study might, after validation, be a good starting point when personalizing OSCC follow‐up. In order to further optimize the guidelines for follow‐up and determine the optimal duration of follow‐up future research should focus on elucidating the benefits and risks of risk‐stratified follow‐up and its influence on survival or quality of life.
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